Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoglitazone dose-response study in T2D
NCT00143520Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivoglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in Glycosylated Hemoglobin at 26 weeks. Started Dec 2004; status: completed.
02
Drugs
rivoglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00143520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143520.